The announcement of the results of the 12-month Part A component of BridgeBio Pharma, Inc.’s ATTRibute-CM study of acoramidis (formerly AG10), in 632 symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM) patients, was supposed to provide a mandate for regulatory submissions. This was because the primary endpoint in the Phase III ATTRibute-CM study was a hard clinical measure – the six-minute walk distance (6MWD). This contrasted with the trial on which Biogen, Inc., gained a much contested and mostly un-reimbursed accelerated approval on the basis of a surrogate marker of disease.
Stock Watch: Bridgebio’s Endpoint A Bridge Too Far
Switch From Surrogate To Clinical Endpoint Between Phase II and III Had Big Risks
The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.
More from Stock Watch
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.
• By
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.
More from Business
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.